Article PDF first page preview

First page of Impact of Subclinical Hypothyroidism on Coagulation Parameters and Coronary Artery Disease Severity in Patients with Coronary Heart Disease

Objective: This study evaluated the effect of subclinical hypothyroidism (SCH) on coagulation parameters and the progression of coronary artery disease (CAD) in patients with coronary heart disease (CHD). Methods: A retrospective analysis was conducted on 452 patients who were diagnosed with CHD through coronary angiography between January 2020 and December 2021 at the Department of Cardiology, Jining First People’s Hospital. The patients were divided into three groups based on thyroid-stimulating hormone (TSH) levels: a normal thyroid function group (244 cases), a mild SCH group (162 cases), and a severe SCH group (46 cases). General demographic data, coagulation parameters, number of affected coronary vessels, stenosis location, and stenosis severity were compared across the groups. Results: (1) Significant differences were observed among the three groups in terms of sex, age, TSH, free triiodothyronine (FT3), free thyroxine (FT4), triglycerides, total cholesterol, low-density lipoprotein cholesterol, fibrinogen, prothrombin time, activated partial thromboplastin time, D-dimer, mean platelet volume, and platelet distribution width (P < 0.05). (2) The Gensini scores were 27 (17, 43.88) for the normal thyroid function group, 37.5 (25, 52.25) for the mild SCH group, and 48 (32.88, 73.75) for the severe SCH group, showing statistically significant differences (P < 0.05). (3) There was a positive correlation between Gensini score and TSH (r = 0.243, P < 0.05) and negative correlations between Gensini score and both FT3 (r = -0.139, P < 0.05) and FT4 (r = -0.12, P < 0.05). (4) TSH level, hypertension history, and lipoprotein(a) were identified as risk factors for Gensini score (P < 0.05). Conclusion: Patients with CHD and SCH present a hypercoagulable state and an elevated risk of thrombosis. TSH levels are linked to the severity of coronary artery stenosis, underscoring the importance of early thyroid function testing in patients with CHD to inform treatment decisions.

Journal Section:
CAD and AMI
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.